Detalhe da pesquisa
1.
Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial.
Lancet Oncol
; 2024 Jun 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-38889735
2.
Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study.
Blood
; 139(18): 2747-2757, 2022 05 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35511184
3.
Acquired von Willebrand syndrome associated with a smoldering multiple myeloma, successfully treated by daratumumab, lenalidomide and dexamethasone.
Acta Haematol
; 2024 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38359808
4.
Whole-body MRI in oncology: can a single anatomic T2 Dixon sequence replace the combination of T1 and STIR sequences to detect skeletal metastasis and myeloma?
Eur Radiol
; 33(1): 244-257, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-35925384
5.
Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients.
Blood
; 136(25): 2881-2892, 2020 12 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-33113551
6.
Imaging of treatment response and minimal residual disease in multiple myeloma: state of the art WB-MRI and PET/CT.
Skeletal Radiol
; 51(1): 59-80, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-34363522
7.
Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial.
Lancet Oncol
; 22(10): 1378-1390, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34529931
8.
Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients.
Blood
; 133(13): 1457-1464, 2019 03 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-30630862
9.
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.
Lancet
; 394(10192): 29-38, 2019 07 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31171419
10.
MRI versus 18F-FDG-PET/CT for detecting bone marrow involvement in multiple myeloma: diagnostic performance and clinical relevance.
Eur Radiol
; 30(4): 1927-1937, 2020 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-31844960
11.
Acquired cutis laxa from heavy chain deposition disease.
Kidney Int
; 102(6): 1432-1433, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36411025
12.
Lenalidomide maintenance after stem-cell transplantation for multiple myeloma.
N Engl J Med
; 366(19): 1782-91, 2012 May 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-22571202
13.
COVID-19, impact on myeloma patients.
Ann Hematol
; 99(8): 1947-1949, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32577846
14.
Favorable effect of priming with granulocyte colony-stimulating factor in remission induction of acute myeloid leukemia restricted to dose escalation of cytarabine.
Blood
; 119(23): 5367-73, 2012 Jun 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-22422824
15.
Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma.
J Clin Oncol
; : JCO2401008, 2024 Jun 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38879802
16.
Long-term follow-up of the imatinib GRAAPH-2003 study in newly diagnosed patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: a GRAALL study.
Biol Blood Marrow Transplant
; 19(1): 150-5, 2013 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-22960387
17.
Ixazomib, daratumumab and low-dose dexamethasone in intermediate-fit patients with newly diagnosed multiple myeloma: an open-label phase 2 trial.
EClinicalMedicine
; 63: 102167, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37680948
18.
Crystalglobulin-Associated Kidney Disease: A Case Report and Literature Review.
Kidney Med
; 4(5): 100445, 2022 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-35479195
19.
Recommendations on the management of multiple myeloma in 2020.
Acta Clin Belg
; 77(2): 445-461, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-33355041
20.
Characterization of haematological parameters with bortezomib-melphalan-prednisone versus melphalan-prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating agents: analysis of the VISTA trial.
Br J Haematol
; 153(2): 212-21, 2011 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-21375521